There is currently no MHRA Early Access to Medicines Scheme (EAMS) designation for retatrutide, meaning no pre-approval access pathway has been established
Other options include pasireotide (which requires blood glucose monitoring due to hyperglycaemia risk), metyrapone , or ketoconazole (used off-label for Cushing's with liver function monitoring)
More than likely, your greater susceptibility to harmful pathogens stems from problems with your immune system defenses
GHK-Cu, on the other hand, works through regenerative pathways enhancing collagen, reducing inflammation, and protecting against oxidative stress
During this consultation, we will discuss your health history, weight loss goals, and any previous attempts at weight loss